Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification

被引:1
作者
Yang, Min [1 ]
Zeng, Lin [2 ]
Hou, Sheng-zhong [3 ]
Ke, Neng-wen [3 ]
Tian, Bo-le [3 ]
Liu, Xu-bao [3 ]
Xiang, Bo [1 ]
Zhang, Yi [3 ]
机构
[1] Sichuan Univ, Dept Pediat Surg, West China Hosp, Chengdu, Sichuan, Peoples R China
[2] Sichuan Univ, President & Deans Off, West China Hosp, Chengdu, Sichuan, Peoples R China
[3] Sichuan Univ, Dept Pancreat Surg, West China Hosp, Chengdu, Sichuan, Peoples R China
关键词
AMERICAN JOINT COMMITTEE; PROGNOSTIC-FACTORS; TUMORS; SYSTEM; G3; CARCINOMAS;
D O I
10.1155/2020/6572398
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Purpose. Neuroendocrine neoplasms occurring in the liver are very rare, in which metastatic hepatic neuroendocrine neoplasms [(MH)-NENs] secondary to gastroenteropancreatic NENs [(GEP)-NENs] account for their majority. The clinical features and long-term survival of (MH)-NENs secondary to (GEP)-NENs were not clear, especially for each grading group of G1 neuroendocrine tumors (NETs), G2 NETs, and G3 NETs and G3 neuroendocrine carcinomas (G3 NECs).Method. Data of patients who were surgically treated and clinicopathologically diagnosed as (MH)-NENs secondary to (GEP)-NENs at West China Hospital of Sichuan University from January 2006 to December 2018 were retrospectively collected and analyzed by the grading classification for (GEP)-NENs.Results. We identified 150 patients with (MH)-NENs secondary to (GEP)-NENs, including 10 patients with G1 NETs, 26 with G2 NETs, 33 with G3 NETs, and 81 with G3 NECs. There were significant differences between patients with G1/G2/G3 NETs and those with G3 NECs, such as age at diagnosis (P=0.041), synchronous liver lesion (P=0.032), incidental diagnosis (P=0.014), tumor largest diameter (P=0.047), vascular invasion (P=0.017), and extrahepatic metastatic disease (P=0.029). The estimated 3-year overall survival for patients with G1 NETs, G2 NETs, G3 NETs, and G3 NECs was 100%, 79.4%, 49.5%, and 20.7%, respectively (P<0.001). The survival of G1 NETs or G2 NETs was significantly better than that of G3 NETs (P=0.013,P=0.037, respectively) and G3 NECs (P=0.001,P<0.001; respectively). Patients with G3 NECs present notably worse survival than those with G3 NETs (P=0.012), while survival comparison between G1 NETs and G2 NETs was not statistically different (P=0.131). The grading classification for (GEP)-NENs was an effective independent predictor of survival for (MH)-NENs secondary to (GEP)-NENs (hazard ratio: 4.234; 95% confidence intervals: 1.984-6.763;P=0.003).Conclusion. Our demonstration revealed that the grading classification for (GEP)-NENs could well stratify (MH)-NENs secondary to (GEP)-NENs into prognostic groups and supported its wide use in clinical practice.
引用
收藏
页数:10
相关论文
共 35 条
[1]  
[Anonymous], 2010, WHO CLASSIFICATION T
[2]   The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms [J].
Basturk, Olca ;
Yang, Zhaohai ;
Tang, Laura H. ;
Hruban, Ralph H. ;
Adsay, Volkan ;
McCall, Chad M. ;
Krasinskas, Alyssa M. ;
Jang, Kee-Taek ;
Frankel, Wendy L. ;
Balci, Serdar ;
Sigel, Carlie ;
Klimstra, David S. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (05) :683-690
[3]   The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications [J].
Cavalcanti, Marcela S. ;
Gonen, Mithat ;
Klimstra, David S. .
INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2016, 3 (03) :203-219
[4]   What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms? [J].
Choe, Jooae ;
Kim, Kyung Won ;
Kim, Hyoung Jung ;
Kim, Dong Wook ;
Kim, Kyu Pyo ;
Hong, Seung-Mo ;
Ryu, Jin-Sook ;
Tirumani, Sree Harsha ;
Krajewski, Katherine ;
Ramaiya, Nikhil .
KOREAN JOURNAL OF RADIOLOGY, 2019, 20 (01) :5-17
[5]  
Crawley FP, 2012, ADDRESS SCI SESSION
[6]   Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas: A SEER Database Analysis of 162,983 Cases [J].
Dasari, Arvind ;
Mehta, Kathan ;
Byers, Lauren A. ;
Sorbye, Halfdan ;
Yao, James C. .
CANCER, 2018, 124 (04) :807-815
[7]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[8]   Survivals of patients with pancreatic neuroendocrine carcinomas An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual [J].
Deng, Ben-Yuan ;
Yang, Min ;
Wen, Jie-Yu ;
Hou, Sheng-Zhong ;
Chen, Yang ;
Tian, Bo-Le ;
Liu, Xu-Bao ;
Zhang, Yi .
MEDICINE, 2020, 99 (03)
[9]   Gastroenteric neuroendocrine neoplasms classification: Comparison of prognostic models [J].
Dolcetta-Capuzzo, Anna ;
Villa, Valentina ;
Albarello, Luca ;
Franchi, Giulia M. ;
Gemma, Marco ;
Scavini, Marina ;
Di Palo, Saverio ;
Orsenigo, Elena ;
Bosi, Emanuele ;
Doglioni, Claudio ;
Manzoni, Marco F. .
CANCER, 2013, 119 (01) :36-44
[10]   Therapeutic Strategies for Neuroendocrine Liver Metastases [J].
Frilling, Andrea ;
Clift, Ashley K. .
CANCER, 2015, 121 (08) :1172-1186